Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8448MR)

This product GTTS-WQ8448MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8448MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14467MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ10040MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ1097MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ13990MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ1560MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ10453MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ9079MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ12384MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW